Asboe D - Search Results

1

Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom.

Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane PA; UK HIV Drug Resistance Database. Mbisa JL, et al. Among authors: asboe d. Clin Infect Dis. 2015 Sep 1;61(5):829-36. doi: 10.1093/cid/civ393. Epub 2015 May 19. Clin Infect Dis. 2015. PMID: 25991470

2

A virological benefit from an induction/maintenance strategy: the Forte trial.

Asboe D, Williams IG, Goodall RL, Darbyshire JH, Hooker MH, Babiker AG; Forte Steering Committee. Asboe D, et al. Antivir Ther. 2007;12(1):47-54. Antivir Ther. 2007. PMID: 17503747 Clinical Trial.

3

The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom.

Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT; UK Collaborative Group on HIV Drug Resistance. Green H, et al. J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):196-204. doi: 10.1097/QAI.0b013e318185725f. J Acquir Immune Defic Syndr. 2008. PMID: 18769348

4

Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals.

Hué S, Gifford RJ, Dunn D, Fernhill E, Pillay D; UK Collaborative Group on HIV Drug Resistance. Hué S, et al. J Virol. 2009 Mar;83(6):2645-54. doi: 10.1128/JVI.01556-08. Epub 2009 Jan 21. J Virol. 2009. PMID: 19158238 Free PMC article.

5

Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.

Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance. Geretti AM, et al. Clin Infect Dis. 2009 May 1;48(9):1296-305. doi: 10.1086/598502. Clin Infect Dis. 2009. PMID: 19331585

6

Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.

Boffito M, Jackson A, Lamorde M, Back D, Watson V, Taylor J, Waters L, Asboe D, Gazzard B, Pozniak A. Boffito M, et al. Among authors: asboe d. J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):222-7. doi: 10.1097/QAI.0b013e3181b061d0. J Acquir Immune Defic Syndr. 2009. PMID: 19620877 Clinical Trial.

7

The impact of the 0-0 cell on measures of amino acid covariation.

Dunn D, von Wyl V, Price H, Asboe D. Dunn D, et al. Among authors: asboe d. AIDS. 2010 Jan 2;24(1):159-60. doi: 10.1097/QAD.0b013e32833156ab. AIDS. 2010. PMID: 19952543 No abstract available.

8

Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.

UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. UK Collaborative Group on HIV Drug Resistance, et al. Clin Infect Dis. 2010 May 1;50(9):1275-85. doi: 10.1086/651684. Clin Infect Dis. 2010. PMID: 20353366

9

Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.

Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study. Price H, et al. Among authors: asboe d. Antivir Ther. 2010;15(2):203-11. doi: 10.3851/IMP1511. Antivir Ther. 2010. PMID: 20386075

10

The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.

Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D; UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study (UK CHIC). Harrison L, et al. AIDS. 2010 Jul 31;24(12):1917-22. doi: 10.1097/QAD.0b013e32833c1d93. AIDS. 2010. PMID: 20588166

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters